- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05099003
Een onderzoek naar het geneesmiddel Selinexor met bestralingstherapie bij patiënten met nieuw gediagnosticeerd diffuus intrinsiek ponsglioom (DIPG) en hooggradig glioom (HGG)
Een fase 1/2-onderzoek met Selinexor (KPT-330) en bestralingstherapie bij nieuw gediagnosticeerde pediatrische diffuus intrinsiek ponsglioom (DIPG) en hooggradig glioom (HGG)
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
PRIMARY OBJECTIVES:
I. To define toxicities and estimate the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of selinexor administered as an oral formulation in combination with standard of care radiation therapy (RT), to pediatric patients with newly diagnosed high-grade glioma (HGG) or diffuse intrinsic pontine glioma (DIPG). (Dose-finding phase/phase I) II. To estimate the event-free survival (EFS) distribution for diffuse midline glioma (DMG)/HGG patients and overall survival (OS) distribution for DIPG patients associated with selinexor plus RT, followed by selinexor in patients with newly diagnosed HGG (H3 K27M mutant DMG or H3 K27-wild type HGG) or DIPG, and to compare those outcomes to historical controls. (Efficacy phase/phase II)
EXPLORATORY OBJECTIVE:
I. To bank tumor specimens and body fluids (blood and cerebrospinal fluid) for future studies.
OUTLINE: This is a phase I dose-escalation study of selinexor followed by a phase II study. (STRATUM DIPG AND STRATUM DMG CLOSED TO ACCRUAL 02/14/2025)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor orally (PO) on days 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a magnetic resonance imaging (MRI) and may undergo a biopsy during screening.
MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up.
After completion of study treatment, patients are followed every 3 months for year 1 (i.e., 3, 6, 9, 12 months), then every 6 months for years 2-3 (i.e., 18, 24, 30, 36 months), and finally once yearly for years 4-5 of this study.
Studietype
Inschrijving (Geschat)
Fase
- Fase 2
- Fase 1
Contacten en locaties
Studie Locaties
-
-
New South Wales
-
Randwick, New South Wales, Australië, 2031
- Sydney Children's Hospital
-
Westmead, New South Wales, Australië, 2145
- The Children's Hospital at Westmead
-
-
Queensland
-
South Brisbane, Queensland, Australië, 4101
- Queensland Children's Hospital
-
-
Victoria
-
Parkville, Victoria, Australië, 3052
- Royal Children's Hospital
-
-
Western Australia
-
Perth, Western Australia, Australië, 6009
- Perth Children's Hospital
-
-
-
-
-
Québec, Canada, G1V 4G2
- CHU de Quebec-Centre Hospitalier de l'Universite Laval (CHUL)
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 2B7
- University of Alberta Hospital
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6H 3V4
- British Columbia Children's Hospital
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3E 0V9
- CancerCare Manitoba
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canada, B3K 6R8
- IWK Health Centre
-
-
Ontario
-
Hamilton, Ontario, Canada, L8N 3Z5
- McMaster Children's Hospital at Hamilton Health Sciences
-
Toronto, Ontario, Canada, M5G 1X8
- Hospital for Sick Children
-
-
Quebec
-
Montreal, Quebec, Canada, H3H 1P3
- The Montreal Children's Hospital of the MUHC
-
Montreal, Quebec, Canada, H3T 1C5
- Centre Hospitalier Universitaire Sainte-Justine
-
Sherbrooke, Quebec, Canada, J1H 5N4
- Centre Hospitalier Universitaire de Sherbrooke-Fleurimont
-
-
Saskatchewan
-
Saskatoon, Saskatchewan, Canada, S7N 0W8
- Jim Pattison Children's Hospital
-
-
-
-
-
Christchurch, Nieuw-Zeeland, 8011
- Christchurch Hospital
-
-
Auckland
-
Grafton, Auckland, Nieuw-Zeeland, 1145
- Starship Children's Hospital
-
-
-
-
Alabama
-
Birmingham, Alabama, Verenigde Staten, 35233
- Children's Hospital of Alabama
-
-
Arizona
-
Mesa, Arizona, Verenigde Staten, 85202
- Banner Children's at Desert
-
Phoenix, Arizona, Verenigde Staten, 85016
- Phoenix Childrens Hospital
-
-
Arkansas
-
Little Rock, Arkansas, Verenigde Staten, 72202-3591
- Arkansas Children's Hospital
-
-
California
-
Loma Linda, California, Verenigde Staten, 92354
- Loma Linda University Medical Center
-
Long Beach, California, Verenigde Staten, 90806
- Miller Children's and Women's Hospital Long Beach
-
Los Angeles, California, Verenigde Staten, 90048
- Cedars-Sinai Medical Center
-
Los Angeles, California, Verenigde Staten, 90027
- Children's Hospital Los Angeles
-
Madera, California, Verenigde Staten, 93636
- Valley Children's Hospital
-
Oakland, California, Verenigde Staten, 94609
- UCSF Benioff Children's Hospital Oakland
-
Oakland, California, Verenigde Staten, 94611
- Kaiser Permanente-Oakland
-
Orange, California, Verenigde Staten, 92868
- Children's Hospital of Orange County
-
Palo Alto, California, Verenigde Staten, 94304
- Lucile Packard Children's Hospital Stanford University
-
San Diego, California, Verenigde Staten, 92123
- Rady Children's Hospital - San Diego
-
San Francisco, California, Verenigde Staten, 94158
- UCSF Medical Center-Mission Bay
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, Verenigde Staten, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Verenigde Staten, 06520
- Yale University
-
-
Delaware
-
Wilmington, Delaware, Verenigde Staten, 19803
- Alfred I duPont Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Verenigde Staten, 20010
- Children's National Medical Center
-
-
Florida
-
Fort Myers, Florida, Verenigde Staten, 33908
- Golisano Children's Hospital of Southwest Florida
-
Jacksonville, Florida, Verenigde Staten, 32207
- Nemours Children's Clinic-Jacksonville
-
Miami, Florida, Verenigde Staten, 33136
- University of Miami Miller School of Medicine-Sylvester Cancer Center
-
Miami, Florida, Verenigde Staten, 33176
- Miami Cancer Institute
-
Orlando, Florida, Verenigde Staten, 32827
- Nemours Children's Hospital
-
Orlando, Florida, Verenigde Staten, 32806
- Arnold Palmer Hospital for Children
-
St. Petersburg, Florida, Verenigde Staten, 33701
- Johns Hopkins All Children's Hospital
-
Tampa, Florida, Verenigde Staten, 33607
- Saint Joseph's Hospital/Children's Hospital-Tampa
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30329
- Children's Healthcare of Atlanta - Arthur M Blank Hospital
-
-
Hawaii
-
Honolulu, Hawaii, Verenigde Staten, 96826
- Kapiolani Medical Center for Women and Children
-
-
Idaho
-
Boise, Idaho, Verenigde Staten, 83712
- Saint Luke's Cancer Institute - Boise
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60637
- University of Chicago Comprehensive Cancer Center
-
Peoria, Illinois, Verenigde Staten, 61637
- OSF Children's Hospital of Illinois
-
-
Indiana
-
Indianapolis, Indiana, Verenigde Staten, 46202
- Riley Hospital for Children
-
-
Iowa
-
Des Moines, Iowa, Verenigde Staten, 50309
- Blank Children's Hospital
-
Iowa City, Iowa, Verenigde Staten, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Verenigde Staten, 40536
- University of Kentucky/Markey Cancer Center
-
Louisville, Kentucky, Verenigde Staten, 40202
- Norton Children's Hospital
-
-
Louisiana
-
New Orleans, Louisiana, Verenigde Staten, 70118
- Children's Hospital New Orleans
-
-
Maine
-
Bangor, Maine, Verenigde Staten, 04401
- Eastern Maine Medical Center
-
Scarborough, Maine, Verenigde Staten, 04074
- Maine Children's Cancer Program
-
-
Maryland
-
Baltimore, Maryland, Verenigde Staten, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02215
- Dana-Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- C S Mott Children's Hospital
-
Detroit, Michigan, Verenigde Staten, 48201
- Children's Hospital of Michigan
-
Grand Rapids, Michigan, Verenigde Staten, 49503
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
-
Minnesota
-
Minneapolis, Minnesota, Verenigde Staten, 55404
- Children's Hospitals and Clinics of Minnesota - Minneapolis
-
Minneapolis, Minnesota, Verenigde Staten, 55455
- University of Minnesota/Masonic Cancer Center
-
-
Mississippi
-
Jackson, Mississippi, Verenigde Staten, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Kansas City, Missouri, Verenigde Staten, 64108
- Children's Mercy Hospitals and Clinics
-
St Louis, Missouri, Verenigde Staten, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Verenigde Staten, 63141
- Mercy Hospital Saint Louis
-
St Louis, Missouri, Verenigde Staten, 63104
- Cardinal Glennon Children's Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Verenigde Staten, 68198
- University of Nebraska Medical Center
-
Omaha, Nebraska, Verenigde Staten, 68114
- Children's Hospital and Medical Center of Omaha
-
-
New Jersey
-
Hackensack, New Jersey, Verenigde Staten, 07601
- Hackensack University Medical Center
-
Morristown, New Jersey, Verenigde Staten, 07960
- Morristown Medical Center
-
New Brunswick, New Jersey, Verenigde Staten, 08903
- Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital
-
Newark, New Jersey, Verenigde Staten, 07112
- Newark Beth Israel Medical Center
-
Paterson, New Jersey, Verenigde Staten, 07503
- Saint Joseph's Regional Medical Center
-
-
New York
-
Albany, New York, Verenigde Staten, 12208
- Albany Medical Center
-
Buffalo, New York, Verenigde Staten, 14263
- Roswell Park Cancer Institute
-
New Hyde Park, New York, Verenigde Staten, 11040
- The Steven and Alexandra Cohen Children's Medical Center of New York
-
New York, New York, Verenigde Staten, 10065
- Memorial Sloan Kettering Cancer Center
-
New York, New York, Verenigde Staten, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
New York, New York, Verenigde Staten, 10016
- Laura and Isaac Perlmutter Cancer Center at NYU Langone
-
Syracuse, New York, Verenigde Staten, 13210
- State University of New York Upstate Medical University
-
The Bronx, New York, Verenigde Staten, 10467
- Montefiore Medical Center - Moses Campus
-
-
North Carolina
-
Charlotte, North Carolina, Verenigde Staten, 28204
- Novant Health Presbyterian Medical Center
-
Greenville, North Carolina, Verenigde Staten, 27834
- East Carolina University
-
Winston-Salem, North Carolina, Verenigde Staten, 27157
- Wake Forest University Health Sciences
-
-
North Dakota
-
Fargo, North Dakota, Verenigde Staten, 58122
- Sanford Broadway Medical Center
-
-
Ohio
-
Akron, Ohio, Verenigde Staten, 44308
- Children's Hospital Medical Center of Akron
-
Cincinnati, Ohio, Verenigde Staten, 45229
- Cincinnati Children's Hospital Medical Center
-
Cleveland, Ohio, Verenigde Staten, 44106
- Rainbow Babies and Childrens Hospital
-
Columbus, Ohio, Verenigde Staten, 43205
- Nationwide Children's Hospital
-
Dayton, Ohio, Verenigde Staten, 45404
- Dayton Children's Hospital
-
Toledo, Ohio, Verenigde Staten, 43606
- ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Verenigde Staten, 73104
- University of Oklahoma Health Sciences Center
-
-
Oregon
-
Portland, Oregon, Verenigde Staten, 97239
- Oregon Health and Science University
-
Portland, Oregon, Verenigde Staten, 97227
- Legacy Emanuel Children's Hospital
-
-
Pennsylvania
-
Danville, Pennsylvania, Verenigde Staten, 17822
- Geisinger Medical Center
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
Philadelphia, Pennsylvania, Verenigde Staten, 19134
- Saint Christopher's Hospital for Children
-
Pittsburgh, Pennsylvania, Verenigde Staten, 15224
- Children's Hospital of Pittsburgh of UPMC
-
-
Rhode Island
-
Providence, Rhode Island, Verenigde Staten, 02903
- Rhode Island Hospital
-
-
South Carolina
-
Columbia, South Carolina, Verenigde Staten, 29203
- Prisma Health Richland Hospital
-
Greenville, South Carolina, Verenigde Staten, 29605
- BI-LO Charities Children's Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Verenigde Staten, 57117-5134
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Verenigde Staten, 37916
- East Tennessee Childrens Hospital
-
Memphis, Tennessee, Verenigde Staten, 38105
- Saint Jude Children's Research Hospital
-
Nashville, Tennessee, Verenigde Staten, 37203
- The Children's Hospital at TriStar Centennial
-
-
Texas
-
Austin, Texas, Verenigde Staten, 78723
- Dell Children's Medical Center of Central Texas
-
Corpus Christi, Texas, Verenigde Staten, 78411
- Driscoll Children's Hospital
-
Dallas, Texas, Verenigde Staten, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, Verenigde Staten, 75230
- Medical City Dallas Hospital
-
El Paso, Texas, Verenigde Staten, 79905
- El Paso Children's Hospital
-
Fort Worth, Texas, Verenigde Staten, 76104
- Cook Children's Medical Center
-
Houston, Texas, Verenigde Staten, 77030
- UT MD Anderson Cancer Center
-
Houston, Texas, Verenigde Staten, 77030
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
San Antonio, Texas, Verenigde Staten, 78229
- University of Texas Health Science Center at San Antonio
-
San Antonio, Texas, Verenigde Staten, 78207
- Children's Hospital of San Antonio
-
Temple, Texas, Verenigde Staten, 76508
- Scott and White Memorial Hospital
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84113
- Primary Children's Hospital
-
-
Virginia
-
Charlottesville, Virginia, Verenigde Staten, 22908
- University of Virginia Cancer Center
-
Norfolk, Virginia, Verenigde Staten, 23507
- Children's Hospital of The King's Daughters
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital
-
Spokane, Washington, Verenigde Staten, 99204
- Providence Sacred Heart Medical Center and Children's Hospital
-
Tacoma, Washington, Verenigde Staten, 98405
- Mary Bridge Children's Hospital and Health Center
-
-
Wisconsin
-
Madison, Wisconsin, Verenigde Staten, 53792
- University of Wisconsin Carbone Cancer Center - University Hospital
-
Milwaukee, Wisconsin, Verenigde Staten, 53226
- Children's Hospital of Wisconsin
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
-
PRE ENROLLMENT: Patients must be =< 25 years of age at the time of enrollment on APEC14B1 part A central nervous system (CNS)/high grade glioma (HGG) pre-enrollment eligibility screening
-
Please note:
- This required age range applies to pre-enrollment eligibility for all HGG patients. Individual treatment protocols may have different age criteria.
- Non-DIPG patients with tumors that do not harbor an H3K27M-mutation and are >= 18 years of age will not be eligible to enroll on ACNS1821 (Step 1).
-
-
PRE ENROLLMENT: Patient is suspected of having localized, newly diagnosed HGG, excluding metastatic disease, OR patient has an institutional diagnosis of DIPG
- Please note: there are specific radiographic criteria for DIPG patient enrollment on ACNS1821 (Step 1)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors: Patients and/or their parents or legal guardians must have signed informed consent for eligibility screening on APEC14B1 Part A.
- For patients with DIPG: Patients and/or their parents or legal guardians must have signed informed consent for ACNS1821.
- Note: As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
-
PRE ENROLLMENT:
- For patients with non-pontine tumors only, the specimens obtained at the time of diagnostic biopsy or surgery must be submitted through APEC14B1 ASAP, preferably within 5 calendar days of definitive surgery
-
STEP 1: Patients must be >= 12 months and =< 21 years of age at the time of enrollment
-
STEP 1: Patients must have newly-diagnosed DIPG or HGG (including DMG).
-
STEP 1: Stratum DIPG (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients with newly-diagnosed typical DIPG, defined as tumors with a pontine epicenter and diffuse involvement of at least 2/3 of the pons on at least 1 axial T2 weighted image, are eligible. No histologic confirmation is required.
- Patients with pontine tumors that do not meet radiographic criteria for typical DIPG (e.g., focal tumors or those involving less than 2/3 of the pontine cross-sectional area with or without extrapontine extension) are eligible if the tumors are biopsied and proven to be high-grade gliomas (such as anaplastic astrocytoma, glioblastoma, high-grade glioma not otherwise specified [NOS], and/or H3 K27M-mutant) by institutional diagnosis.
-
STEP 1: Stratum DMG (with H3 K27M mutation) (Closed with Amendment #4)
- As of February 14, 2025, stratum DIPG and stratum DMG have closed to accrual, and no patients will be enrolled on these strata after Amendment #4.
- Patients must have newly-diagnosed non-pontine H3 K27M-mutant HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
- Note: Patients need not have either measurable or evaluable disease, i.e., DMG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment. For rare H3 K27M-mutant HGG in non-midline structures (e.g., cerebral hemispheres), these patients will be considered part of Stratum DMG.
-
STEP 1: Stratum HGG (without H3 K27M mutation)
-
Patients must have newly-diagnosed non-pontine H3 K27M-wild type HGG without BRAF V600 or IDH1 mutations as confirmed by Rapid Central Pathology and Molecular Screening Reviews performed on APEC14B1
-
Please note:
- Patients who fall in this category and who are >= 18 years of age are not eligible due to another standard-of-care regimen (radiation/temozolomide) that is available
- Patients need not have either measurable or evaluable disease, i.e., HGG patients may have complete resection of their tumor prior to enrollment. Primary spinal tumors are eligible for enrollment
-
-
STEP 1: Patients must have a performance status corresponding to Eastern Cooperative Oncology Group (ECOG) scores of 0, 1 or 2. Use Karnofsky for patients > 16 years of age and Lansky for patients =<16 years of age. Patients who are unable to walk because of paralysis, but who are up in a wheelchair, will be considered ambulatory for the purpose of assessing the performance score.
-
STEP 1: Peripheral absolute neutrophil count (ANC) >= 1000/uL (within 7 days prior to step 1 enrollment)
-
STEP 1: Platelet count >= 100,000/uL (transfusion independent) (within 7 days prior to step 1 enrollment)
-
STEP 1: Hemoglobin >= 8.0 g/dL (may receive red blood cell [RBC] transfusions) (within 7 days prior to step 1 enrollment)
-
STEP 1: Creatinine clearance or radioisotope glomerular filtration rate (GFR) >= 70 mL/min/1.73 m^2 (within 7 days prior to step 1 enrollment) or
A serum creatinine based on age/sex as follows (within 7 days prior to step 1 enrollment):
-
Age / Maximum Serum Creatinine (mg/dL)
-
1 to < 2 years / male: 0.6; female: 0.6
-
2 to < 6 years / male: 0.8; female: 0.8
-
6 to < 10 years / male: 1; female: 1
-
10 to < 13 years / male: 1.2; female: 1.2
-
13 to < 16 years / male: 1.5; female: 1.4
-
>= 16 years / male: 1.7; female: 1.4
- STEP 1: Total bilirubin =< 1.5 x upper limit of normal (ULN) for age
- STEP 1: Serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 135 U/L. For the purpose of this study, the ULN for SGPT is 45 U/L.
- STEP 1: Serum amylase =< 1.5 x ULN
- STEP 1: Serum lipase =< 1.5 x ULN
- STEP 1: No evidence of dyspnea at rest, no exercise intolerance, and a pulse oximetry > 94% if there is clinical indication for determination.
- STEP 1: Patients with seizure disorder may be enrolled if on anticonvulsants and well controlled.
- STEP 1: Patients must be enrolled and protocol therapy must begin no later than 31 days after the date of radiographic diagnosis (in the case of non-biopsied DIPG patients only) or definitive surgery, whichever is the later date (Day 0).
-
For patients who have a biopsy followed by resection, the date of resection will be considered the date of definitive diagnostic surgery. If a biopsy only was performed, the biopsy date will be considered the date of definitive diagnostic surgery.
Exclusion Criteria:
-
STEP 1: Patients must not have received any prior therapy for their central nervous system (CNS) malignancy except for surgery and steroid medications.
-
STEP 1: Patients who are currently receiving another investigational drug are not eligible.
-
STEP 1: Patients who are currently receiving other anti-cancer agents are not eligible.
-
STEP 1: Patients >=18 years of age who have H3 K27M-wild type HGG.
-
STEP 1: Patients who have an uncontrolled infection.
-
STEP 1: Patients who have received a prior solid organ transplantation.
-
STEP 1: Patients with grade > 1 extrapyramidal movement disorder.
-
STEP 1: Patients with known macular degeneration, uncontrolled glaucoma, or cataracts.
-
STEP 1: Patients with metastatic disease are not eligible; MRI of spine with and without contrast must be performed if metastatic disease is suspected by the treating physician.
-
STEP 1: Patients with gliomatosis cerebri type 1 or 2 are not eligible, with the exception of H3 K27M-mutant bithalamic tumors.
-
STEP 1: Patients who are not able to receive protocol specified radiation therapy.
-
STEP 1:
- Female patients who are pregnant are ineligible since there is yet no available information regarding human fetal or teratogenic toxicities.
- Lactating females are not eligible unless they have agreed not to breastfeed their infants. It is not known whether selinexor is excreted in human milk.
- Female patients of childbearing potential are not eligible unless a negative pregnancy test result has been obtained.
- Sexually active patients of reproductive potential are not eligible unless they have agreed to use two effective methods of birth control (including a medically accepted barrier method of contraception, e.g., male or female condom) for the duration of their study participation and for 90 days after the last dose of selinexor. Abstinence is an acceptable method of birth control.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Treatment (selinexor and radiation therapy)
CHEMORADIOTHERAPY: Patients receive standard of care radiation therapy 5 days per week for 5-7 weeks. Starting on day 4 or 5 of radiation therapy, patients receive selinexor PO on 1, 8, 15, 22, 29, 36, 43, and 50 in the absence of disease progression or unacceptable toxicity. After a 2-week rest period, patients proceed to Maintenance. Patients undergo a MRI and may undergo a biopsy during screening. MAINTENANCE: Patients receive selinexor PO on days 1, 8, 15, and 22 of each cycle. Cycles repeat every 28 days for up to 24 cycles of maintenance therapy in the absence of disease progression or unacceptable toxicity. Patients undergo a MRI on study and during follow-up. |
Undergo radiation therapy
Andere namen:
Undergo a MRI
Andere namen:
Undergo a biopsy
Andere namen:
Given orally
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maximum tolerated dose
Tijdsspanne: From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
Defined as the highest dose of selinexor in combination with standard of care radiation therapy that does not cause unacceptable side effects. |
From day 1 of selinexor treatment until the start of maintenance therapy, assessed up to 10 weeks from treatment start date
|
|
Event free survival (EFS)
Tijdsspanne: From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse midline glioma/ high grade glioma patients. EFS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until disease progression date, secondary malignant neoplasm occurrence date, death date of any cause, or last follow-up date, assessed up to 5 years
|
|
Overall Survival (OS)
Tijdsspanne: From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
Will be calculated for diffuse intrinsic pontine glioma patients. The OS curve will be estimated by Kaplan Meier estimates. |
From the date of enrollment until death date of any cause or last follow-up date, assessed up to 5 years
|
|
Overall response rate
Tijdsspanne: Up to 5 years
|
Defined as the proportion of patients whose best response is partial response or complete response. |
Up to 5 years
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Adam L Green, Children's Oncology Group
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
- Neoplasmata
- Neoplasmata per histologisch type
- Neoplasmata, glandulair en epitheel
- Neoplasmata, neuro-epitheliaal
- Neuro-ectodermale tumoren
- Neoplasmata, kiemcellen en embryonaal
- Neoplasmata, zenuwweefsel
- Glioom
- Onderzoekstechnieken
- Therapeutica
- Exemplaarbehandeling
- Klinische laboratoriumtechnieken
- Diagnostische technieken en procedures
- Diagnose
- Chirurgische procedures, operatief
- Cytologische technieken
- Cytodiagnose
- Fysieke fenomeen
- Diagnostische technieken, chirurgisch
- Chemie -technieken, analytisch
- Spectrumanalyse
- Radiotherapie
- Bestraling
- Biopsie
- Magnetische resonantiespectroscopie
- selinexor
Andere studie-ID-nummers
- NCI-2021-11337
- U10CA180886 (Subsidie/contract van de Amerikaanse NIH)
- NCI-2021-11337 (Register-ID: CTRP (Clinical Trial Reporting Program))
- ACNS1821 (Andere identificatie: CTEP)
- ACNS1821 (Andere identificatie: Children's Oncology Group)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
product vervaardigd in en geëxporteerd uit de V.S.
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .